• Nexstim received an order for one NBS 6 therapy system from an existing private healthcare customer in Finland.
• The buyer will add a second NBS 6 to expand its service offering.
• NBS 6 is CE-marked for major depression treatment, chronic neuropathic pain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nexstim Oyj published the original content used to generate this news brief on July 31, 2026, and is solely responsible for the information contained therein.